ARTICLE | Finance
OrbiMed turns True North
What True North plans to do with $35M B round led by OrbiMed
April 13, 2015 7:00 AM UTC
An untranched $35 million series B round will give True North Therapeutics Inc. runway to move its lead program targeting the complement pathway into the clinic this quarter and a second program into the clinic next year. Beyond that CEO Nancy Stagliano said the biotech is keeping its funding options open.
New investor OrbiMed led last week's round. Existing investors Kleiner Perkins Caufield & Byers, MPM Capital, SR One, and Baxter Ventures participated...